It is noteworthy that meanwhile, one of the drugs used for treating AD is an NMDA receptor antagonist [118] and that treatment with JNK inhibitors such as D-JNKI1, SP600125 or TAT-JNK-III protects against glutamate excitotoxicity and cell death in vivo and in vitro [119,120,121]. Here, MAPK8 is linked to Alzheimer disease.